- Home
- KOD vs TLSI Comparison
KOD vs TLSI Comparison
Compare KOD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- TLSI
- Stock Information
- Founded
- KOD 2009
- TLSI 2010
- Country
- KOD United States
- TLSI United States
- Employees
- KOD N/A
- TLSI N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- TLSI Medical Specialities
- Sector
- KOD Health Care
- TLSI Health Care
- Exchange
- KOD Nasdaq
- TLSI Nasdaq
- Market Cap
- KOD N/A
- TLSI 160.4M
- IPO Year
- KOD 2018
- TLSI N/A
- Fundamental
- Price
- KOD $2.67
- TLSI $5.50
- Analyst Decision
- KOD Hold
- TLSI Strong Buy
- Analyst Count
- KOD 4
- TLSI 6
- Target Price
- KOD $8.00
- TLSI $11.75
- AVG Volume (30 Days)
- KOD 361.7K
- TLSI 69.6K
- Earning Date
- KOD 03-27-2025
- TLSI 03-27-2025
- Dividend Yield
- KOD N/A
- TLSI N/A
- EPS Growth
- KOD N/A
- TLSI N/A
- EPS
- KOD N/A
- TLSI N/A
- Revenue
- KOD N/A
- TLSI $29,431,000.00
- Revenue This Year
- KOD N/A
- TLSI $55.43
- Revenue Next Year
- KOD N/A
- TLSI $50.09
- P/E Ratio
- KOD N/A
- TLSI N/A
- Revenue Growth
- KOD N/A
- TLSI 58.99
- 52 Week Low
- KOD $2.19
- TLSI $3.50
- 52 Week High
- KOD $11.60
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- KOD 30.00
- TLSI 49.81
- Support Level
- KOD $2.97
- TLSI $5.36
- Resistance Level
- KOD $2.86
- TLSI $5.72
- Average True Range (ATR)
- KOD 0.26
- TLSI 0.34
- MACD
- KOD 0.02
- TLSI 0.00
- Stochastic Oscillator
- KOD 15.57
- TLSI 70.22
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.